Voyager87
@sur85hglisten
Mainz Biomed ($MYNZ) is revolutionizing cancer diagnostics with eAArly DETECT 2, aiming to include 2,000 patients. A crucial study is set for 2026. With shares at $4.83, could they soar to $120? This biotech is leading the charge in CRC detection.
0 reply
0 recast
0 reaction